UC DAVIS (US) — An anti-anxiety drug available in Europe helps protect nerve fibers and slows the progression of symptoms of multiple sclerosis (MS) in mice, a study shows. The findings, published online in the journal EMBO Molecular Medicine , could have therapeutic applications for MS as well as cerebral palsy and leukodystrophies, all disorders associated with loss of white ...

By Vrinda Manocha (Reuters) - XenoPort Inc said it would stop development of an experimental multiple sclerosis treatment it planned to launch in 2015 after a late-stage trial failed to show significant improvement over a placebo. Shares of the company fell 26 percent to $5.03 in morning trade on the Nasdaq. "This is disappointing, given (the drug's) promising mid-stage data," ...

(Reuters) - XenoPort Inc said it will stop developing its experimental multiple sclerosis treatment after data from a late-stage trial showed the drug did not improve patients' condition significantly compared with a placebo. The company said it will shut down all activities related to the drug, arbaclofen placarbil, and planned to provide an update on the impact of the expected ...

(SACRAMENTO, Calif.) — Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved medications against MS.

BY KRISTA CONGER - Blocking the expression of just one protein in the brain delays the onset of paralysis in mice with a form of multiple sclerosis, say researchers at the School of Medicine.